Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.35 |
| ▸ | TDO2 | P48775 | 2/20 | 0.35 |
| ▸ | SCN4A | P35499 | 5/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.34 |
| ▸ | BCDIN3D | Q7Z5W3 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | AGXT | P21549 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23215033 | 1.00 | IDO1 (0.35) | IDO1TDO2SCN4AAOC3BCDIN3D | |
| SCHEMBL31739155 | 0.84 | TACR1 (0.42) | IDO1TACR1 | |
| SCHEMBL16761917 | 0.84 | SCN4A (0.32) | IDO1SCN4ATACR1 | |
| SCHEMBL16793913 | 0.84 | DPP4 (0.35) | IDO1SCN4ADPP4TACR1 | |
| SCHEMBL1850702 | 0.83 | SCN4A (0.49) | SCN4ATACR1 | |
| SCHEMBL22502109 | 0.83 | SCN4A (0.49) | SCN4ATACR1 | |
| SCHEMBL366662 | 0.83 | SCN4A (0.49) | SCN4ATACR1 | |
| SCHEMBL31739159 | 0.83 | CYP1A2 (0.50) | IDO1AOC3TACR1AGXT | |
| SCHEMBL1516258 | 0.82 | DPP4 (0.37) | SCN4ABCDIN3DDPP4TACR1ADRB2 | |
| SCHEMBL2524000 | 0.81 | GABBR2 (0.42) | IDO1TDO2AOC3ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12565501-B2 | Muscarinic acetylcholine M1 receptor antagonists | CONTINEUM THERAPEUTICS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250171455-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2025-05-29 | — | — | US | disclosed |
| US-20230089921-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| CN-114729044-A | Muscarinic acetylcholine M1Receptor antagonists | 帕珀莱恩医疗公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021071843-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | Pipeline Therapeutics, Inc. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-8487099-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487099-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120107328-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2012-05-03 | — | — | US | disclosed |
| US-20100256128-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107328-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | IDO1 4504/4885TDO2 4780/4885SCN4A 1045/4885 |
| US-20100256128-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | IDO1 4402/4885TDO2 4797/4885SCN4A 672/4885 |
| US-12565501-B2 | Muscarinic acetylcholine M1 receptor antagonists | CHRM1, CHRM2, CHRM3 | IDO1 764/4885TDO2 2155/4885SCN4A 506/4885 |
| US-20230089921-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM3 | IDO1 613/4885TDO2 3046/4885SCN4A 1000/4885 |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM5, CHRM3 | IDO1 785/4885TDO2 2000/4885SCN4A 360/4885 |
| US-20250171455-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM3 | IDO1 604/4885TDO2 3048/4885SCN4A 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.